2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. (Q53243856)

12 May 2018

title

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. (English)

1 reference

12 May 2018

1 reference

1 reference

1 reference

9

1 reference

12 May 2018

Andrew M. Wardley

16

1 reference

12 May 2018

Josep Baselga

10

Jose Baselga

1 reference

12 May 2018

8

Michael Untch

1 reference

12 May 2018

6

Mitch Dowsett

1 reference

12 May 2018

5

Andrea Feyereislova

1 reference

12 May 2018

Aron Goldhirsch

7

Aron Goldhirsch

1 reference

12 May 2018

Marion Procter

2

Marion Procter

1 reference

12 May 2018

Nadia Harbeck

17

Nadia Harbeck

1 reference

12 May 2018

author name string

Ian Smith

1

1 reference

12 May 2018

Richard D Gelber

3

1 reference

12 May 2018

Sébastien Guillaume

4

1 reference

12 May 2018

Manfred Kaufmann

11

1 reference

12 May 2018

David Cameron

12

1 reference

12 May 2018

Richard Bell

13

1 reference

12 May 2018

Jonas Bergh

14

1 reference

12 May 2018

Robert Coleman

15

1 reference

12 May 2018

Roberto I Lopez

18

1 reference

12 May 2018

Peter Mallmann

19

1 reference

12 May 2018

Karen Gelmon

20

1 reference

12 May 2018

Nicholas Wilcken

21

1 reference

12 May 2018

Erik Wist

22

1 reference

12 May 2018

Pedro Sánchez Rovira

23

1 reference

12 May 2018

Martine J Piccart-Gebhart

24

1 reference

12 May 2018

HERA study team

25

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 January 2007

1 reference

12 May 2018

published in

The Lancet

1 reference

12 May 2018

volume

369

1 reference

12 May 2018

issue

9555

1 reference

12 May 2018

page(s)

29-36

1 reference

12 May 2018

The discovery of receptor tyrosine kinases: targets for cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Herceptin and early breast cancer: a moment for caution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Trastuzumab in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960028-2

7 January 2021

10.1016/S0140-6736(07)60028-2

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018